has developed a new product for the treatment and prevention of bacterial vaginosis to meet the needs of women for efficacy, safety and user-friendliness. Laccure’s novel, non-prescription vaginal tablet has been tested in randomized, controlled clinical multicenter studies including 126 women. The results show a cure rate of 80 percent following a single administration of one (1) vaginal tablet. Along with a good safety profile and by fully meeting women’s need for user-friendly comfort, this represents a major improvement in the treatment of bacterial vaginosis.
Laccure AB was founded in 2007. In 2017 Laccure AB and Combe Inc., an international personal care company, signed an agreement awarding Combe the exclusive license to market and sell Laccure’s female health product globally. The license arrangement was terminated in the beginning of 2019 and Laccure continues to pursue commercialization.